



- (51) International Patent Classification:  
C08G 63/06 (2006.01)
- (21) International Application Number:  
PCT/US2014/039970
- (22) International Filing Date:  
29 May 2014 (29.05.2014)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
61/828,534 29 May 2013 (29.05.2013) US
- (71) Applicant: RUTGERS, THE STATE UNIVERSITY OF  
NEW JERSEY [US/US]; Old Queens Building, Somerset  
and George Streets, New Brunswick, New Jersey 08903  
(US).
- (72) Inventors: UHRICH, Kathryn; Old Queens Building,  
Somerset and George Streets, New Brunswick, New Jersey  
08903 (US). MORANO, Michelle; Old Queens Building,  
Somerset and George Streets, New Brunswick, New Jersey  
08903 (US).
- (74) Agents: KRUEGER, Katherine A.D. et al.; 7900 Interna-  
tional Drive, Suite 670, Bloomington, Minnesota 55425  
(US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,  
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,  
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: ANTIOXIDANT-BASED POLY(ANHYDRIDE-ESTERS)

Figure 1



(57) Abstract: Certain embodiments of the invention provide antioxidant-based diacids and polymers comprising glycol groups as described herein, and methods of use thereof. In certain embodiments the polymers described herein are formulated as microspheres or hydrogels. Described herein is the chemical incorporation of antioxidants, e.g., coumaric acid, ferulic acid, and sinapic acid, into a polymer backbone for use, e.g., in applications for localized release and rapid delivery. As provided, the chemical composition of the linker molecules used (of which hold together two bioactives via ester linkages) may be used to vary the hydrophilicity of the polymer. The bioactive release rate may also be altered for a tunable release delivery system, allowing for increased bioactive release compared to other linkers previously utilized.



- 
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

## **ANTIOXIDANT-BASED POLY(ANHYDRIDE-ESTERS)**

### **GOVERNMENT FUNDING**

This invention was made with government support under Grant Number P200A120078 awarded by the Department of Education and under Grant Number R01 DE013207 awarded by the National Institutes of Health. The government has certain rights in the invention.

### **CROSS-REFERENCE TO RELATED APPLICATION**

This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 61/828,534, filed May 29, 2013, the entire contents of which is hereby incorporated by reference.

### **BACKGROUND OF THE INVENTION**

There is significant evidence demonstrating the role of antioxidants in protecting cells from free radical species. Free radicals have been identified as major sources of oxidative stress in cells leading to DNA damage. This increased oxidative stress has been implicated in various deleterious conditions including cardiovascular diseases, neurodegenerative diseases, and cancer, while also contributing to the physiology of ageing. The human body combats this oxidative stress by employing antioxidants made in the body or acquired from diet and/or supplements. These antioxidants, however, are usually not in sufficient levels to overcome the damage from oxidative stress accumulation. Therefore, there has been much effort in the development of topical antioxidants with photoprotective and therapeutic efficacy.

Ferulic acid is a hydroxycinnamic acid and potent ubiquitous plant antioxidant due to its phenolic and extended side chain conjugation, which forms a resonance-stabilized phenolic radical. Ferulic acid has been studied as an ultra-violet absorber for enhanced skin protection against photodamage and has been approved as a sunscreen in Japan. While ferulic acid can be quite useful, its limited elimination half-life (less than 2 hours) and stability issues (degradation over time) lower its efficacy in current formulations.

Accordingly, new antioxidant compositions (e.g., ferulic acid compositions) are needed.

### SUMMARY OF THE INVENTION

Accordingly, certain embodiments of the invention provide a diacid or polymer as described herein.

Certain embodiments of the invention provide a microsphere comprising a polymer as described herein.

Certain embodiments of the invention provide a pharmaceutical composition comprising a diacid, polymer or microsphere as described herein and a pharmaceutically acceptable carrier.

Certain embodiments of the invention provide a cosmetic comprising a diacid, polymer or microsphere as described herein.

Certain embodiments of the invention provide a sunscreen comprising a diacid, polymer or microsphere as described herein.

Certain embodiments of the invention provide a method to reduce oxidative stress in a mammalian cell (e.g., a human cell), comprising administering a diacid, polymer or microsphere as described herein to the mammal.

Certain embodiments of the invention provide a method to prevent photodamage to a mammal's skin (e.g. human), comprising administering a diacid, polymer or microsphere as described herein to the mammal.

Certain embodiments of the invention provide a method to treat a disorder associated with oxidative stress in a mammal (e.g., human), comprising administering a diacid, polymer or microsphere as described herein to the mammal.

Certain embodiments of the invention provide a hydrogel comprising (a) a polymer as described herein; and (b) a hydrophilic polymer that is blended with the polymer of part (a).

Certain embodiments of the invention provide a method of making a hydrogel as described herein, comprising solvent casting (a) a polymer as described herein; and (b) a hydrophilic polymer; under conditions to provide a hydrogel.

Certain embodiments of the invention provide a method for promoting wound healing in a mammal, comprising contacting a hydrogel as described herein with a wound of the mammal.

Certain embodiments of the invention provide a method of therapeutically treating the skin of a mammal, comprising contacting a hydrogel as described herein with the skin of the mammal.

Certain embodiments of the invention provide a method of making a diacid, polymer, microsphere or hydrogel as described herein.

Certain embodiments of the invention provide a diacid, polymer, microsphere or hydrogel prepared by the methods described herein.

### BRIEF DESCRIPTION OF THE FIGURES

**Figure 1.** Examples of ferulic acid-containing poly(anhydride-esters) and FA-containing diacids with various linker molecules.

**Figure 2.** Synthesis of ferulic acid-containing poly(anhydride-esters) (**5**) and FA-containing polymer precursors including diacids (**4**) and *t*-butyl intermediates (**3**) with varying linkers (**a** (Ouimet, *Biomacromolecules* **2013**, *14*, 854–61), **b**, **c**). Polymers, precursors and intermediates with comprising other bioactives described herein, such as coumaric acid or sinapic acid, may be similarly synthesized. Additionally, polymers, precursors and intermediates with comprising other linker molecules described herein may also be similarly synthesized.

**Figure 3.** <sup>1</sup>H NMR spectra of ferulic acid (diglycolic) polymer and each intermediate step. *t*-butyl ferulic acid (diglycolic) intermediate **3b** (A), ferulic acid (diglycolic) **4b** (B), and ferulic acid (diglycolic) polymer, **5b** (C) spectra are illustrated above.

**Figure 4.** <sup>1</sup>H NMR spectra of ferulic acid (tetraglycolic) polymer and each intermediate step. *t*-butyl ferulic acid (tetraglycolic) intermediate **3c** (A), ferulic acid (tetraglycolic) **4c** (B), and ferulic acid (tetraglycolic) polymer, **5c** (C) spectra are illustrated above.

**Figure 5.** Percent cumulative ferulic acid (FA) release over time for ferulic acid (adipic) polymer (**5a**), ferulic acid (diglycolic) polymer (**5b**), and ferulic acid (tetraglycolic) polymer (**5c**).

**Figure 6.** Change of degradation media pH over time during *in vitro* studies.


**Figure 7.** Percent DPPH reduction for the ferulic acid (adipic) polymer (**5a**), ferulic acid (diglycolic) polymer (**5b**), and ferulic acid (tetraglycolic) polymer (**5c**) as compared to free ferulic acid (control).

**Figure 8.** (A) Representative scanning electron microscopy images of microspheres prepared from the FA-containing polymer with a diglycolic linker. (B) *In vitro* ferulic acid release from polymer microspheres (diglycolic linker) (FA ± standard deviation).

### DETAILED DESCRIPTION

Described herein is the chemical incorporation of antioxidants, e.g., coumaric acid, ferulic acid, and sinapic acid, into a polymer backbone for use, e.g., in applications for localized release and rapid delivery. As shown herein, the chemical composition of the linker molecules used (of which hold together two bioactives via ester linkages) may be used to vary the hydrophilicity of the polymer. The bioactive release rate may also be altered for a tunable release delivery system, allowing for increased bioactive release compared to other linkers previously utilized. Moreover, the polymer properties (thermal, mechanical, etc.) may also be tuned by altering the linker molecule. Overall, these tunable polymers may improve the quality, aesthetics, and performance of a product.

Accordingly, certain embodiments of the invention provide a diacid selected from:



wherein  $R_1$  is  $OCH_3$  and  $R_2$  is H;  $R_1$  is  $OCH_3$  and  $R_2$  is  $OCH_3$ ; or  $R_1$  is H and  $R_2$  is H;  
and

wherein  $y$  is 4 or more.



In certain embodiments,  $y$  is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more.

In certain embodiments,  $R_1$  is  $OCH_3$  and  $R_2$  is H.


In certain embodiments,  $R_1$  is  $OCH_3$  and  $R_2$  is  $OCH_3$ .

In certain embodiments,  $R_1$  is H and  $R_2$  is H.

Certain embodiments of the invention provide a polymer selected from:



and



wherein  $R_1$  is  $OCH_3$  and  $R_2$  is H;  $R_1$  is  $OCH_3$  and  $R_2$  is  $OCH_3$ ; or  $R_1$  is H and  $R_2$  is H;

wherein  $y$  is 4 or more;

and wherein  $n$  is 2 or more.

In certain embodiments,  $n$  is 3 or more. In certain embodiments,  $n$  is 4 or more. In certain embodiments,  $n$  is 5 or more. In certain embodiments,  $n$  is less than 2,000. In certain embodiments,  $n$  is less than 1,000. In certain embodiments,  $n$  is less than 500. In certain embodiments,  $n$  is less than 250. In certain embodiments,  $n$  is less than 150. In certain embodiments,  $n$  is less than 100. In certain embodiments,  $n$  is from about 5 to about 100. In certain embodiments,  $n$  is from about 5 to about 90. In certain embodiments,  $n$  is from about 5 to about 80. In certain embodiments,  $n$  is from about 5 to about 70. In certain

embodiments,  $n$  is from about 5 to about 60. In certain embodiments,  $n$  is from about 10 to about 30. In certain embodiments,  $n$  is from about 10 to about 20. In certain embodiments,  $n$  is about 10.

In certain embodiments,  $y$  is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more.

In certain embodiments,  $R_1$  is  $\text{OCH}_3$  and  $R_2$  is H.

In certain embodiments,  $R_1$  is  $\text{OCH}_3$  and  $R_2$  is  $\text{OCH}_3$ .

In certain embodiments,  $R_1$  is H and  $R_2$  is H.

In certain embodiments, the polymer has an average molecular weight of about 1,000 daltons to about 100,000 daltons. In certain embodiments, the polymer has an average molecular weight of about 5,000 daltons to about 100,000 daltons. In certain embodiments, the polymer has an average molecular weight of about 5,000 daltons to about 50,000 daltons. In certain embodiments, the polymer has an average molecular weight of about 10,000 daltons to about 30,000 daltons.


Certain embodiments of the invention provide a diacid as described herein.




Certain embodiments of the invention provide a polymer as described herein.

The polymers as described herein may be processed into microspheres using known methods and procedures commonly employed in the field of synthetic polymers, *e.g.*, as described in the Examples.


Accordingly, certain embodiments of the invention provide a microsphere comprising a polymer as described herein.

Certain embodiments of the invention provide a microsphere comprising a polymer selected from:





and



wherein  $R_1$  is  $OCH_3$  and  $R_2$  is H;  $R_1$  is  $OCH_3$  and  $R_2$  is  $OCH_3$ ; or  $R_1$  is H and  $R_2$  is H;

wherein  $y$  is 4 or more;

and wherein  $n$  is 2 or more.

In certain embodiments,  $n$  is 3 or more. In certain embodiments,  $n$  is 4 or more. In certain embodiments,  $n$  is 5 or more. In certain embodiments,  $n$  is less than 2,000. In certain embodiments,  $n$  is less than 1,000. In certain embodiments,  $n$  is less than 500. In certain

embodiments, n is less than 250. In certain embodiments, n is less than 150. In certain embodiments, n is less than 100. In certain embodiments, n is from about 5 to about 100. In certain embodiments, n is from about 5 to about 90. In certain embodiments, n is from about 5 to about 80. In certain embodiments, n is from about 5 to about 70. In certain embodiments, n is from about 5 to about 60. In certain embodiments, n is from about 10 to about 30. In certain embodiments, n is from about 10 to about 20. In certain embodiments, n is about 10.

In certain embodiments, y is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more.

In certain embodiments, the diameter of the microsphere is between about 2  $\mu\text{m}$  to about 100  $\mu\text{m}$ . In certain embodiments, the diameter of the microsphere is between about 2  $\mu\text{m}$  to about 90  $\mu\text{m}$ . In certain embodiments, the diameter of the microsphere is between about 2  $\mu\text{m}$  to about 80  $\mu\text{m}$ . In certain embodiments, the diameter of the microsphere is between about 2  $\mu\text{m}$  to about 70  $\mu\text{m}$ . In certain embodiments, the diameter of the microsphere is between about 2  $\mu\text{m}$  to about 60  $\mu\text{m}$ . In certain embodiments, the diameter of the microsphere is between about 2  $\mu\text{m}$  to about 50  $\mu\text{m}$ . In certain embodiments, the diameter of the microsphere is between about 2  $\mu\text{m}$  to about 40  $\mu\text{m}$ . In certain embodiments, the diameter of the microsphere is between about 2  $\mu\text{m}$  to about 30  $\mu\text{m}$ .

Additional agents, synthetic or natural, may be incorporated in the microsphere described herein to achieve enhanced biological, mechanical, or other desired properties. Accordingly, in certain embodiments the microsphere comprises an additional agent(s) (e.g., the agent may be encapsulated by the microsphere). In certain embodiments, the additional agent(s) is a bioactive agent. For example, the additional bioactive agent may be encapsulated by the microspheres, resulting in a microsphere with a dual release of bioactive agents. In certain embodiments, the additional bioactive agent(s) is the same as the bioactive in the polymer backbone (e.g., ferulic acid, coumaric acid or sinapic acid). In certain embodiments, the additional bioactive agent(s) is different from the bioactive in the polymer backbone. In certain embodiments, the additional agent is an antioxidant, an antimicrobial, a sunscreen, a UV-absorber, a dye, a pigment or preservative.

Certain embodiments of the invention provide a composition comprising a diacid, polymer or microsphere as described herein and a carrier.

Certain embodiments of the invention provide a pharmaceutical composition comprising a diacid, polymer or microsphere as described herein and a pharmaceutically acceptable carrier.

Certain embodiments of the invention provide a cosmetic comprising a diacid, polymer or microsphere as described herein.

Certain embodiments of the invention provide a sunscreen comprising a diacid, polymer or microsphere as described herein.

Certain embodiments of the invention provide a method to reduce oxidative stress in a mammalian cell (e.g., a human cell), comprising administering a diacid, polymer or microsphere as described herein to the mammal. For example, the diacid, polymer or microsphere may be administered to the mammal by contacting the mammalian cell with the diacid, polymer or microsphere (e.g., through topical administration).

Oxidative stress is typically defined as the condition in which the sum of free radicals (i.e., reactive oxygen species) within cells are greater than the antioxidant capacity of the cell, thus creating an imbalance. Disorders associated with oxidative stress are known to those skilled in the art, and include, e.g., cancer, such as skin cancer, as well as aspects related to the physiology of aging, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis, cardiovascular disorders such as atherosclerosis, cardiovascular disease, and hypertension, type II diabetes, age-related macular degeneration, osteoarthritis, and osteoporosis.

Certain embodiments of the invention provide a method to prevent photodamage to a mammal's skin (e.g. human), comprising administering a diacid, polymer or microsphere as described herein to the mammal. Photodamage to the skin is typically defined as the structural and functional deterioration of sun-exposed skin, resulting in wrinkling, roughness, altered texture, discoloration, acral lentigines, mottled hyperpigmentation, epidermal thickness, basophilic degeneration of dermis, collagen, dermal vessels, epithelial atypia, and/or dysplasia.

In certain embodiments, the diacid, polymer or microsphere is administered topically.

Certain embodiments of the invention provide a method to treat a disorder associated with oxidative stress in a mammal (e.g., human), comprising administering a diacid, polymer or microsphere as described herein to the mammal.

Certain embodiments of the invention provide a diacid, polymer or microsphere as described herein for use in medical treatment.

Certain embodiments of the invention provide the use of a diacid, polymer or microsphere as described herein to prepare a medicament useful for reducing oxidative stress in a mammalian cell (e.g., a human cell).

Certain embodiments of the invention provide the use of a diacid, polymer or microsphere as described herein to prepare a medicament useful for preventing photodamage to a mammal's skin.

Certain embodiments of the invention provide the use of a diacid, polymer or microsphere as described herein to prepare a medicament useful for treating a disorder associated with oxidative stress in a mammal.

Certain embodiments of the invention provide a diacid, polymer or microsphere as described herein for use in reducing oxidative stress.

Certain embodiments of the invention provide a diacid, polymer or microsphere as described herein for use in preventing photodamage to a mammal's skin.

Certain embodiments of the invention provide a diacid, polymer or microsphere as described herein for use in treating a disorder associated with oxidative stress in a mammal.

The polymers as described herein may be processed into hydrogels using known methods and procedures, *e.g.*, as described in US Patent Publication US 2013/0022569, which is hereby incorporated by reference.

Accordingly, certain embodiments of the invention provide a hydrogel comprising a polymer as described herein. Typically, hydrogels are three-dimensional hydrophilic crosslinked polymer networks that can absorb large volumes of water and biological fluids without dissolving.

Certain embodiments of the invention provide a hydrogel comprising (a) a polymer as described herein; and (b) a hydrophilic polymer that is blended with the polymer of part (a).

In certain embodiments, the term "blend" may refer to crosslinking, wherein the hydrophilic polymer is crosslinked to the polymer described herein. As used herein, the term "crosslink" can refer to physical (*e.g.*, intermolecular interactions or entanglements, such as through hydrophobic interactions) or chemical crosslinking (*e.g.*, covalent bonding). Chemical crosslinking may be induced for these hydrogels using ultraviolet (UV) radiation, gamma radiation, an external cross-linking agent, or Fenton and photo-Fenton reactions to obtain chemical hydrogels. This chemical crosslinking may result in a more stable and non-reversible material, wherein the polymer described herein is trapped within the three-dimensional network of the hydrophilic polymer.

Accordingly, in certain embodiments, the polymer as described herein is physically crosslinked with the hydrophilic polymer through hydrophobic interactions.

In certain embodiments, the polymer described herein is chemically crosslinked with the hydrophilic polymer.

In certain embodiments, the polymer described herein is covalently crosslinked with the hydrophilic polymer.

In certain embodiments, the polymer described herein is crosslinked with the hydrophilic polymer using a free radical mechanism.

In certain embodiments, the ratio of the polymer as described herein and the hydrophilic polymer ranges between about 1:9 to about 1:1.

In certain embodiments, the ratio of the polymer described herein to the hydrophilic polymer ranges between about 1:9 to about 4:6. In certain embodiments, the ratio of the polymer described herein to the hydrophilic polymer ranges between about 1:9 to about 3:7. In certain embodiments, the ratio of the polymer described herein to the hydrophilic polymer ranges between about 1:9 to about 2:8. In certain embodiments, the ratio of the polymer described herein to the hydrophilic polymer is about 1:9. In certain embodiments, the ratio of the polymer described herein to the hydrophilic polymer is about 2:8. In certain embodiments, the ratio of the polymer described herein to the hydrophilic polymer is about 3:7. In certain embodiments, the ratio of the polymer described herein to the hydrophilic polymer is about 4:6. In certain embodiments, the ratio of the polymer described herein to the hydrophilic polymer is about 1:1.

As used herein, a "hydrophilic polymer" is a water-soluble polymer.

In certain embodiments, hydrophilic polymers capable of producing physical or chemical crosslinking in general with the polymers described herein may be used (*e.g.*, polyvinylpyrrolidone (PVP), poly(vinyl alcohol) (PVA), polyurethane (PU) or poly(ethylene oxide)(PEO)).

Accordingly, in certain embodiments, the hydrophilic polymer comprises poly(N-vinyl-2-pyrrolidone), poly(vinyl alcohol), polyurethane or poly(ethylene oxide).

In certain embodiments, the hydrophilic polymer is poly(N-vinyl-2-pyrrolidone).

In certain embodiments, the hydrophilic polymer is a copolymer or blend of two or more polymers.

In certain embodiments, the two or more polymers are selected from poly(N-vinyl-2-pyrrolidone), poly(vinyl alcohol), polyurethane and poly(ethylene oxide).

In certain embodiments, the hydrophilic polymer as described herein has an average molecular weight of about 40,000 daltons to about 2,000,000 daltons. In certain embodiments, the hydrophilic polymer as described herein has an average molecular weight of about 100,000 daltons to about 2,000,000 daltons. In certain embodiments, the hydrophilic polymer as described herein has an average molecular weight of about 500,000 daltons to

about 2,000,000 daltons. In certain embodiments, the hydrophilic polymer as described herein has an average molecular weight of about 750,000 daltons to about 2,000,000 daltons. In certain embodiments, the hydrophilic polymer as described herein has an average molecular weight of about 1,000,000 daltons to about 2,000,000 daltons. In certain embodiments, the hydrophilic polymer as described herein has an average molecular weight of about 1,000,000 daltons to about 1,750,000 daltons. In certain embodiments, the hydrophilic polymer as described herein has an average molecular weight of about 1,000,000 daltons to about 1,500,000 daltons. In certain embodiments, the hydrophilic polymer as described herein has an average molecular weight of about 1,300,000 daltons.

Additional bioactive molecules, synthetic or natural, may be incorporated in the hydrogels described herein to achieve enhanced biological or mechanical properties. For example, free bioactive molecules (*e.g.*, curcumin) may be incorporated into the blended solution for hydrogel production, resulting in a material with dual release of bioactive molecules.

Accordingly, in certain embodiments, the hydrogel further comprises a bioactive molecule dispersed in the hydrogel.

In certain embodiments, the bioactive molecule dispersed in the hydrogel is the same as the bioactive molecule yielded by hydrolysis of the polymer backbone.

In certain embodiments, the bioactive molecule dispersed in the hydrogel is different from the bioactive molecule yielded by hydrolysis of the polymer backbone.

In certain embodiments, the bioactive molecule dispersed in the hydrogel is selected from ferulic acid, sinapic acid, coumaric acid (*e.g.*, *p*-coumaric acid), salicylic acid and curcumin.

In certain embodiments the bioactive molecule dispersed in the hydrogel is curcumin.

As described herein, the synthesis of the hydrogels (*e.g.*, the bioactive-based PVP/polyanhydride blended materials), may be prepared as films by solvent-cast methods. As described herein, the materials may be produced at varying ratios to achieve the desired formulation.

Certain embodiments of the invention provide a method of making a hydrogel as described herein, comprising solvent casting (a) a polymer as described herein; and (b) a hydrophilic polymer; under conditions to provide a hydrogel.

In certain embodiments, the solvent is DMF. In certain embodiments, the solvent is DMSO.

Certain embodiments further comprise cross-linking the polymer as described herein with the hydrophilic polymer using ultraviolet radiation, gamma radiation or an external cross-linking agent.

Certain embodiments of the invention provide a method for promoting wound healing in a mammal, comprising contacting a hydrogel as described herein with a wound (e.g., a burn) of the mammal (e.g., a human).

Certain embodiments of the invention provide a method of therapeutically treating the skin of a mammal, comprising contacting a hydrogel as described herein with the skin of the mammal (e.g., a human).

Certain embodiments of the invention provide the use of a hydrogel as described herein to prepare a medicament useful for promoting wound healing in a mammal.

Certain embodiments of the invention provide the use of a hydrogel as described herein to prepare a medicament useful for therapeutically treating the skin of a mammal.

Certain embodiments of the invention provide a hydrogel as described herein for use in promoting wound healing in a mammal.

Certain embodiments of the invention provide a hydrogel as described herein for use in therapeutically treating the skin of a mammal.

Certain embodiments of the invention provide a hydrogel as described herein for use in therapy.

Certain embodiments provide a hydrogel as described herein.

Certain embodiments of the invention provide a method of making a diacid, polymer, microsphere or hydrogel as described herein.

Certain embodiments of the invention provide a diacid, polymer, microsphere or hydrogel prepared by the methods described herein.

The invention also provides processes and intermediates disclosed herein that are useful for preparing diacids, polymers, microspheres and hydrogels described herein.

As used herein, the terms "treat" and "treatment" can refer to therapeutic treatment or to prophylactic or preventative treatment, wherein the object is to prevent or decrease an undesired physiological change or disorder, such as disorders associated with oxidative stress (e.g., cancer (e.g., skin cancer) or the physiology of aging).

The polymers and diacids of the invention can be formulated as compositions, *e.g.*, pharmaceutical compositions, cosmetics and sunscreens, and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, *e.g.*, orally or parenterally, by intravenous, intramuscular, topical or

subcutaneous routes.

Thus, the present polymers and diacids may be systemically administered. Such compositions and preparations should contain at least 0.1% of the polymers or diacids. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 90% of the weight of a given unit dosage form. The amount of the polymers or diacids in such therapeutically useful compositions is such that an effective dosage level will be obtained.

For topical administration, the present polymers or diacids may be applied in pure form, *e.g.*, when they are liquids, or may be applied as solutions. It will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.

Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina, nanoparticles, and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the polymers or diacids can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.

Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.

The polymers can be formatted into microspheres, using known emulsion methods, or formatted into gels, using known hydrophilic polymers. The microspheres can be dispersed within creams, pastes, oils and the like for topical administration. Similarly, the polymers can be blended into gels with known hydrophilic polymers for topical administration.

Examples of useful dermatological compositions which can be used to deliver the present polymers to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).

Useful dosages of polymers and diacids of the invention can be determined by comparing their *in vitro* activity, and *in vivo* activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art;

for example, see U.S. Pat. No. 4,938,949.

The amount of the polymers or diacids of the invention, required for use in treatment will vary with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.

Certain embodiments of the invention will now be illustrated by the following non-limiting Examples.

### EXAMPLE 1


*Ferulic acid-containing polymers with glycol functionality for tailoring physicochemical properties and release profiles.*

The synthesis of a series of ferulic acid-containing polymers with aliphatic linkages have been achieved via solution polymerization methods. These compounds feature slower release rates than that desired for topical applications. Therefore, there is a need for a more rapid release rate for use in skin care formulations. To demonstrate this, a series of ferulic acid-containing polymers with ethylene glycol linkages were synthesized via solution polymerization methods. The polymers were characterized using nuclear magnetic resonance and Fourier transform infrared spectroscopies. The molecular weights and thermal properties were also determined. The glass transition temperatures and contact angles were obtained and the polymers compared. The polymer chemical structures and physical properties were shown to impact the release rates and antioxidant activity as drug delivery systems demonstrating the ability to strategically select polymers for various applications.

### **Introduction**

Currently, there is significant evidence demonstrating the role of antioxidants in protecting cells from free radical species. Free radicals have been identified as major sources of oxidative stress in cells leading to DNA damage (Orrenius et al., *Annu Rev Pharmacol Toxicol* **2007**, 47, 143-83). This increased oxidative stress has been implicated in various deleterious conditions including cardiovascular diseases, neurodegenerative diseases, and cancer (Vokurkova et al., *Future Cardiol* **2007**, 3, 53-63), while also contributing to the physiology of ageing (Kregel KC, Zhang HJ, *AJP: Regulatory, Integrative and Comparative Physiology* **2006**, 292, R18-R36). The human body combats this oxidative stress by employing antioxidants made in the body or acquired from diet and/or supplements (Podda M, Grundmann-Kollmann M, *Clin Exp Dermatol* **2001**, 26, 578-82; Kohen R, Gati I, *Toxicology* **2000**, 148, 149-57). These antioxidants, however, are usually not in sufficient

levels to overcome the damage from oxidative stress accumulation. Therefore, there has been much effort in the development of topical antioxidants with photoprotective and therapeutic efficacy.



ferulic acid, **1**

**Compound 1.** Chemical structure of the bioactive ferulic acid with many beneficial properties.

Ferulic acid is a hydroxycinnamic acid and potent ubiquitous plant antioxidant due to its phenolic and extended side chain conjugation, which forms a resonance stabilized phenolic radical (Graf E, *Free Radical Bio Med* **1992**, *13*, 435-48). Ferulic acid has been studied as an ultra-violet absorber for enhanced skin protection against photodamage and has been approved as a sunscreen in Japan. While ferulic acid can be quite useful, its limited elimination half-life (less than 2 hours) (Li et al., *Int J Pharm* **2006**, *324*, 152-7) and stability issues (degradation over time) lower its efficacy in current formulations (Wang et al., *J Cosmet Sci* **2011**, *62*, 483-503). Ferulic acid delivery can thus be improved by incorporation into a biodegradable polymer backbone (Ouimet et al., *Biomacromolecules* **2013**, *14*, 854–61), enabling controlled bioactive release and preventing active functional groups from degradation (Wang et al., *J Cosmet Sci* **2011**, *62*, 483-503; Ouimet et al., *Biomacromolecules* **2013**, *14*, 854–61). In this previously designed polymer, ferulic acid was stabilized (i.e., degradation and discoloration did not occur) and antioxidant activity was comparable to that of the free bioactive, indicating ferulic acid maintained its bioactivity over time (Ouimet et al., *Biomacromolecules* **2013**, *14*, 854–61).

Although this polymer demonstrated that ferulic acid could be stabilized via covalent incorporation into a polymer backbone, limited amounts of ferulic acid were released upon polymer degradation over the timeframe studied. For applications where a larger amount of ferulic acid is needed, increased drug release must be attained. A means to thus increase polymer degrade rates is to incorporate ethylene glycol functionalities into the polymer via copolymerization with poly(ethylene glycol) (PEG) or to incorporate ethylene glycol groups within the monomer unit. As described herein, ethylene glycol groups were employed as the

linker molecule between two ferulic acid molecules allowing for increased hydrophilicity and tuning polymer physicochemical properties.

The development of tunable ferulic acid-containing biodegradable polymers by introducing ethylene glycol functionality as a linker molecule is described herein. By incorporating glycol groups into the polymer backbone, increased degradation rates were hypothesized. The synthesis, characterization, and drug release profiles of the glycol-modified polymers are discussed below.

### **Materials and Methods**

**Materials.** 1 N hydrochloric acid (HCl), poly(vinylidene fluoride) and poly(tetrafluoroethylene) syringe filters, and Wheaton glass scintillation vials were purchased from Fisher Scientific (Fair Lawn, NJ). All other reagents, solvents, and fine chemicals were purchased from Aldrich (Milwaukee, WI) and used as received.

**$^1\text{H}$  and  $^{13}\text{C}$  NMR and FT-IR spectroscopies.**  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were recorded on a Varian 400 MHz or 500 MHz spectrometer using deuterated chloroform ( $\text{CDCl}_3$ ) with TMS as internal reference or deuterated dimethyl sulfoxide ( $\text{DMSO}-d_6$ ) as solvent and internal reference. FT-IR spectra were obtained using a Thermo Nicolet/Avatar 360 spectrometer, samples (1 wt %) ground and pressed with KBr into a disc. Each spectrum was an average of 32 scans.

**Molecular Weight.** Polymer precursors were analyzed via mass spectrometry to determine molecular weights. A Finnigan LCQ-DUO equipped with Xcalibur software and an adjustable atmospheric pressure ionization electrospray ion source (API-ESI Ion Source) was used with a pressure of  $0.8 \times 10^{-5}$  and 150 °C API temperature. Samples dissolved in methanol ( $< 10 \mu\text{g/mL}$ ) were injected with a glass syringe. GPC was used to determine polymer weight-averaged molecular weight and polydispersity using a Perkin-Elmer liquid chromatography system consisting of a Series 200 refractive index detector, a Series 200 LC pump, and an ISS 200 autosampler. Automation of the samples and processing of the data was performed using a Dell OptiPlex GX110 computer running Perkin-Elmer TurboChrom 4 software with a Perkin-Elmer Nelson 900 Series Interface and 600 Series Link. Polymer samples were prepared for autoinjection by dissolving in dichloromethane (DCM, 10 mg/mL) and filtering through 0.45  $\mu\text{m}$  poly(tetrafluoroethylene) syringe filters. Samples were resolved on a Jordi divinylbenzene mixed-bed GPC column (7.8 x 300 mm, Alltech Associates, Deerfield, IL) at 25 °C, with DCM as the mobile phase at a flow rate of 1.0 mL/min. Molecular weights were calibrated relative to broad polystyrene standards (Polymer

Source Inc., Dorval, Canada).

**Thermal Properties.** DSC measurements were carried out on TA Instrument Q200 to determine melting ( $T_m$ ) and glass transition ( $T_g$ ) temperatures. Measurements on samples (4-6 mg) heated under nitrogen atmosphere from  $-10\text{ }^{\circ}\text{C}$  to  $200\text{ }^{\circ}\text{C}$  at a heating rate of  $10\text{ }^{\circ}\text{C}/\text{min}$  and cooled to  $-10\text{ }^{\circ}\text{C}$  at a rate of  $10\text{ }^{\circ}\text{C}/\text{min}$  with a two-cycle minimum were performed. TA Instruments Universal Analysis 2000 software, version 4.5A was used to analyze the data. TGA was utilized for determining decomposition temperatures ( $T_d$ ) using a Perkin-Elmer Pyris 1 system with TAC 7/DX instrument controller and Perkin-Elmer Pyris software for data collection. Samples (5-10 mg) were heated under nitrogen atmosphere from  $25\text{ }^{\circ}\text{C}$  to  $400\text{ }^{\circ}\text{C}$  at a heating rate of  $10\text{ }^{\circ}\text{C}/\text{min}$ . Decomposition temperatures were measured at the onset of thermal decomposition.

***t*-Butyl FA (2) Synthesis.** This was prepared according to previously published methods (see, Figure 2, 2) (Ouimet et al., *Biomacromolecules* **2013**, *14*, 854–61; Hu et al., *J Chem Res-S* **2006**, 586-8).

***t*-Butyl FA-containing Diester Intermediate (3) Synthesis.** *t*-Butyl FA (2) (2 eq) was dissolved in anhydrous dimethylformamide (DMF) to which sodium hydride (NaH, 2.2 eq) was added slowly. After 30 minutes, acyl chloride (1 eq) dissolved in 10 mL DMF was added drop-wise at 20 mL/hr. Reaction progress was monitored by thin layer chromatography (5:1 hexane:ethyl acetate as eluent). Once completed, the reaction mixture was diluted with ethyl acetate (250 mL) and washed with deionized water (2 x 100 mL). The organic layer was collected, dried over  $\text{MgSO}_4$ , and the solvents removed *in vacuo*. This was purified on silica gel via flash chromatography using 5:1 hexane:ethyl acetate as eluent.

***t*-Butyl FA-containing (diglycolic) Diester Intermediate (3b).** Diglycolyl chloride (1eq) was used as the acyl chloride. Yield: 72 % (white powder).  $^1\text{H-NMR}$  (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.56 (d, 2H,  $J=16.0\text{ Hz}$ , R-CH=CH-R), 7.10 (s, 2H, Ar-H), 7.09 (d, 2H, Ar-H), 7.08 (d, 2H, Ar-H), 6.34 (d, 2H,  $J=16.0\text{ Hz}$ , R-CH=CH-R), 4.62 (s, 4H,  $\text{CH}_2$ ), 3.86 (s, 6H,  $\text{OCH}_3$ ), 1.54 (s, 18H, 3 $\text{CH}_3$ ).  $^{13}\text{C-NMR}$  ( $\text{CDCl}_3$ ):  $\delta$  167.9, 166.3, 151.3, 142.8, 140.7, 134.3, 123.2, 121.4, 120.9, 111.3, 80.9, 68.1, 56.2, 28.4.  $T_m$ :  $222\text{--}223\text{ }^{\circ}\text{C}$ .

***t*-Butyl FA-containing (tetraglycolic) Diester Intermediate (3c).** To prepare the acyl chloride, 3,6,9-trioxaundecanedioic acid, termed tetraglycolic acid, (1 eq) was reacted neat in thionyl chloride (8 eq) and heated to reflux for 24 hours to yield a yellow liquid, termed tetraglycolyl dichloride. Tetraglycolyl dichloride (1 eq) was used directly as the acyl chloride.  $^1\text{H-NMR}$  (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.55 (d, 2H,  $J=16.0\text{ Hz}$ , R-CH=CH-R), 7.10 (s, 2H,

Ar-H), 7.08 (d, 2H, Ar-H), 7.06 (d, 2H, Ar-H), 6.32 (d, 2H,  $J=16.0$  Hz, R-CH=CH-R), 4.45 (s, 4H, CH<sub>2</sub>), 3.84 (s, 6H, OCH<sub>3</sub>), 3.78 (t, 4H, CH<sub>2</sub>), 3.76 (t, 4H, CH<sub>2</sub>), 1.54 (s, 18H, 3CH<sub>3</sub>). <sup>13</sup>C-NMR (CDCl<sub>3</sub>):  $\delta$  168.6, 166.3, 151.4, 142.9, 141.2, 134.1, 123.2, 121.3, 120.8, 111.3, 80.9, 71.2, 70.9, 68.6, 56.1, 28.4.  $T_m$ : 239-242 °C.

**FA-containing Diacid (4) Synthesis.** Compound 3 (1 eq) was dissolved in anhydrous DCM to which trifluoroacetic acid (TFA) (40 eq) was added and left to stir overnight. Solvent was removed *in vacuo* and the residue was triturated with DI water (300 mL), isolated via vacuum filtration, and dried *in vacuo* for 24 hours.

**FA-containing (diglycolic) Diacid (4b).** Yield: 84 % (white powder). <sup>1</sup>H-NMR (500 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  12.43 (s, 2H, COOH), 7.58 (d, 2H,  $J=16.0$  Hz, R-CH=CH-R), 7.51 (s, 2 H, Ar-H), 7.29 (d, 2H, Ar-H), 7.20 (d, 2H, Ar-H), 6.60 (d, 2H,  $J=16.0$  Hz, R-CH=CH-R), 4.60 (s, 4H, CH<sub>2</sub>), 3.84 (s, 6H, OCH<sub>3</sub>). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  171.6, 168.3, 151.8, 144.0, 141.5, 133.9, 123.8, 122.1, 120.2, 112.5, 56.6, 33.5, 24.4. IR (KBr, cm<sup>-1</sup>): 3000-2500 (OH, COOH), 1752 (C=O, ester), 1696 (C=O, COOH), 1633 and 1600 (C=C).  $T_m$ : 241-244 °C. ESI-MS  $m/z$ : 485 *z*-1.

**FA-containing (tetraglycolic) Diacid (4c).** Yield: 98 % (white crystals). <sup>1</sup>H-NMR (500 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  12.40 (s, 2H, COOH), 7.51 (d, 2H,  $J=16.0$  Hz, R-CH=CH-R), 7.41 (s, 2 H, Ar-H), 7.18 (d, 2H, Ar-H), 7.08 (d, 2H, Ar-H), 6.52 (d, 2H,  $J=16.0$  Hz, R-CH=CH-R), 4.35 (s, 4H, CH<sub>2</sub>), 3.74 (s, 6H, OCH<sub>3</sub>), 3.62 (t, 4H, CH<sub>2</sub>), 3.54 (t, 4H, CH<sub>2</sub>). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  169.0, 168.3, 151.7, 144.0, 140.9, 134.2, 123.8, 122.1, 120.4, 112.7, 70.8, 70.3, 68.1, 56.8. IR (KBr, cm<sup>-1</sup>): 2920 (OH, COOH), 1780 (C=O, ester), 1690 (C=O, COOH), 1630 and 1600 (C=C).  $T_m$ : 86-89 °C. ESI-MS  $m/z$ : 597 [*z* + Na]

**FA-containing Polymer (5) Synthesis.** Polymer (5) was prepared using a modified version of a previously described procedure (Figure 2) (Schmeltzer et al., *J Biomater Sci Polym Ed* 2008, 19, 1295-306). Diacid 4 (1 eq) was dissolved in 20 mL anhydrous DCM under argon. After adding triethylamine (NEt<sub>3</sub>, 4.4 eq), the reaction mixture was cooled to 0 °C. Triphosgene (0.33 eq) dissolved in 10 mL anhydrous DCM was added drop-wise (20 mL/h). The reaction was allowed to stir at 0 °C until CO<sub>2</sub> evolution ceased (ca. 6 h). The reaction mixture was poured over chilled diethyl ether (400 mL) and the precipitate was isolated via vacuum filtration. The residue was dissolved in anhydrous DCM, washed with acidic water (1 x 250 mL), dried over MgSO<sub>4</sub>, concentrated, and precipitated with an excess

of chilled diethyl ether (500 mL). Ether was filtered off via vacuum filtration and polymer dried *in vacuo* at room temperature.

**FA-containing (diglycolic) Polymer (5b).** Yield: 84 % (white powder). <sup>1</sup>H-NMR (500 MHz, DMSO-*d*<sub>6</sub>): 7.93 (d, 2H, *J*=16.0 Hz, R-CH=CH-R), 7.66 (s, 2 H, Ar-H), 7.45 (d, 2H, Ar-H), 7.28 (d, 2H, Ar-H), 6.94 (d, 2H, *J*=16.0 Hz, R-CH=CH-R), 4.63 (s, 4H, CH<sub>2</sub>), 3.86 (s, 6H, OCH<sub>3</sub>). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>): δ 168.3, 163.4, 151.8, 148.7, 141.8, 133.6, 124.0, 123.2, 118.0, 113.4, 67.9, 56.9. IR (KBr, cm<sup>-1</sup>): 1780-1710 (C=O, anhydride and ester region), 1630 and 1600 (C=C). *M*<sub>w</sub> = 18,300 Da, PDI = 1.3. *T*<sub>g</sub> = 108 °C. *T*<sub>d</sub> = 338 °C.

**FA-containing (tetraglycolic) Polymer (5c).** Yield: 90 % (light beige powder). <sup>1</sup>H-NMR (500 MHz, DMSO-*d*<sub>6</sub>): 7.87 (b, 2H, *J*=16.0 Hz, R-CH=CH-R), 7.58 (b, 2 H, Ar-H), 7.38 (b, 2H, Ar-H), 7.20 (b, 2H, Ar-H), 6.86 (b, 2H, *J*=16.0 Hz, R-CH=CH-R), 4.42 (b, 4H, CH<sub>2</sub>), 3.81 (b, 6H, OCH<sub>3</sub>), 3.66 (b, 4H, CH<sub>2</sub>), 3.48 (b, 4H, CH<sub>2</sub>). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>): δ 168.9, 163.3, 151.8, 148.6, 141.8, 133.4, 124.0, 123.1, 117.9, 113.2, 70.8, 70.3, 68.1, 59.8. IR (KBr, cm<sup>-1</sup>): 1800-1710 (C=O, anhydride and ester region), 1630 and 1600 (C=C). *M*<sub>w</sub> = 15,400 Da, PDI = 1.4. *T*<sub>g</sub> = 49 °C. *T*<sub>d</sub> = 251 °C.

**Relative Diacid (4) Hydrophobicity** (Meng QC, Zou H, Johansson JS, Eckenhoff RG, *Anal Biochem* **2001**, 292, 102-6; OECD Nuclear Energy Agency., Organisation for Economic Co-operation and Development. Partition coefficient (1-octanol/water), High Performance Liquid Chromatography (HPLC) Method. Paris: Organisation for Economic Co-Operation and Development; 2004). A polymeric reverse-phase C<sub>18</sub> (RP18) column was used to measure the diacid hydrophobicity. Studies were performed on an XTerra® RP18 5 μm 4.6x150 mm column (Waters, Milford, MA) on a Waters 2695 Separations Module equipped with a Waters 2487 Dual λ Absorbance Detector using a mobile phase consisting of 50 mM KH<sub>2</sub>PO<sub>4</sub> with 1 % formic acid in DI water at pH 2.5 (65 %) and acetonitrile (35 %) run at 1 mL/min flow rate at ambient temperature using λ = 255 and 275 nm for reference samples and λ = 320 nm for diacid samples. HPLC was carried out after all samples were filtered using 0.22 μm poly(vinylidene fluoride) syringe filters and subsequently injected (20 μL) using an autosampler. Samples were prepared in phosphate buffered saline (PBS). The phase preference is expressed by capacity factor *k'*, where *k'* can be calculated using Equation 1, and *t<sub>R</sub>* and *t<sub>0</sub>* are the retention times of the sample and PBS, respectively.

$$k' = (t_R - t_0) / t_0 \quad \text{Equation 1}$$

$$\log P_{o,w} = \text{slope} * \log k' + y\text{-intercept} \quad \text{Equation 2}$$

Toluene, thymol, anisole, and benzyl alcohol were used as reference samples and their retention times obtained. A calibration curve was generated using published  $\log P_{o,w}$  values (OECD Nuclear Energy Agency., Organisation for Economic Co-operation and Development. Partition coefficient (1-octanol/water), High Performance Liquid Chromatography (HPLC) Method. Paris: Organisation for Economic Co-Operation and Development; 2004.) for the reference samples plotted on the y – axis and calculated  $\log k'$  values for the x – axis. This curve was used to find the extrapolated  $\log P$  diacid values of the regression line using Equation 2.

**Contact Angle Measurements for Polymer.** Static contact angles were measured by dropping deionized water onto pressed polymer discs using a Ramé-Hart Standard Goniometer Model Number 250-00 156 (Mountain Lakes, NJ) outfitted with a Dell Dimension 3000 computer with DROPimage Advanced software.

**Polymer swelling measurements.** Triplicate samples of polymer discs were prepared by pressing ground polymer ( $50 \pm 5$  mg) into 8 mm diameter x 1 mm thick discs in an IR pellet die (International Crystal Laboratories, Garfield, NJ) with a bench-top hydraulic press (Carver model M, Wabash, IN). Pressure of 10,000 psi was applied for 10 min at room temperature. All weights were measured gravimetrically. The dry weights were measured by subtracting the vial weight from the weight of the vial with polymer. Samples were submerged in 10 mL PBS. Media was removed at regular time intervals using a pipet before weighing the polymer inside the vial (wet weight) and subsequently drying under vacuum for 24 hours. Swelling was calculated according to Equation 3 where  $w_w$  is wet weight and  $w_d$  is dry weight.

$$[(W_w - w_d) / w_d] * 100 \quad \text{Equation 3}$$

**In Vitro FA Release.** Polymer degradation was measured as a function of FA release. Triplicate samples of polymer discs were prepared by pressing ground polymer ( $50 \pm 5$  mg) into 8 mm diameter x 1 mm thick discs in an IR pellet die (International Crystal Laboratories, Garfield, NJ) with a bench-top hydraulic press (Carver model M, Wabash, IN). Pressure of 10,000 psi was applied for 10 min at room temperature. This methodology was preferred as it minimized interferences from external effects (e.g., formulation additives) on polymer degradation. The PBS pH was adjusted to 7.40 using 1 N sodium hydroxide. All pH measurements were performed using an Accumet® AR15 pH meter (Fisher Scientific, Fair Lawn, NJ).

FA release was monitored by placing polymer discs into 20 mL Wheaton glass scintillation vials with 10 mL of PBS and incubated at 37 °C with agitation at 60 rpm using a controlled environment incubator-shaker (New Brunswick Scientific Co., Edison, NJ). Media was collected every 24 hours for 20 days and replaced with fresh PBS (10 mL). Spent media was analyzed via high-performance liquid chromatography (HPLC). The degradation products were analyzed and quantified via HPLC using an XTerra® RP18 5  $\mu$ m 4.6x150 mm column (Waters, Milford, MA) on a Waters 2695 Separations Module equipped with a Waters 2487 Dual  $\lambda$  Absorbance Detector. All samples were filtered using 0.22  $\mu$ m poly(vinylidene fluoride) syringe filters and subsequently injected (20  $\mu$ L) using an autosampler. The mobile phase was comprised of 50 mM KH<sub>2</sub>PO<sub>4</sub> with 1 % formic acid in DI water at pH 2.5 (65 %) and acetonitrile (35 %) run at 1 mL/min flow rate at ambient temperature. Absorbance was monitored at  $\lambda$  = 320 nm. Amounts were calculated from known concentrations of standard FA solutions.

**Antioxidant Activity.** The degradation antioxidant activity was assessed and compared to free ferulic acid using a 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay. Antioxidant activity was evaluated by adding sample (0.1 mL) to a 0.024 mg/mL DPPH solution in methanol (3.9 mL). Day-10 samples (0.1 mL) from the each polymer degradation media were mixed with the 0.024 mg/mL DPPH solution (3.9 mL) at room temperature. After 1 hour, solutions were analyzed via UV/vis with a Perkin-Elmer Lambda XLS spectrophotometer (Waltham, MA) ( $\lambda$  = 517 nm). Fresh FA solutions prepared at specific concentrations corresponding to day-10 HPLC data were each analyzed identically to the aforementioned degradation media samples. DPPH % radical reduction was calculated by:  $[(Abs_{t0} - Abs_t)/Abs_{t0}] \times 100$ , where  $Abs_{t0}$  is the initial absorbance and  $Abs_t$  is the absorbance after 1 hour. Absorbance values from adding PBS (0.1 mL) to the DPPH solution (3.9 mL) was used as  $Abs_{t0}$ . All radical scavenging assays were performed in triplicate. Student's t-tests were performed to determine significant differences between free FA and FA degradation media antioxidant activity ( $p < 0.05$ ).

## Results and discussion

**Synthesis and Characterization.** Polymers were successfully prepared by chemically incorporating ferulic acid into the backbone via ester and anhydride bonds. The commercial availability of diglycolyl chloride was beneficial, which was not the case for tetraglycolyl chloride. Tetraglycolic acid, which was commercially available, was acylated using thionyl chloride to obtain a dichlorinated molecule. The acyl chloride (both tetraglycolic and

diglycolic) were each separately reacted with *t*-butyl ferulic acid to yield **3** (Figures 2, 3A and 4A), and subsequently deprotected using TFA, denoted by the *t*-butyl group disappearance at 1.54 ppm. The synthesized diacid (**4**, Figures 2, 3B and 4B) underwent solution polymerization using triphosgene as a coupling agent to yield polymer (Figure 2, 3C and 4C). A successful synthesis of each step was fully characterized.

Polymer properties' results are listed in Table 1. Polymers were obtained in  $M_w$  values ranging from 15,400- 21,700 Da with 1.3 – 1.7 PDI values. Ferulic acid loading was modified using the different linker structures; as linker mass increased, ferulic acid chemically incorporated in the polymer backbone decreased giving a **5a** > **5b** > **5c** drug loading trend. Glass transition and decomposition temperatures decreased with increasing linker chain length due to the enhanced flexibility. The trend in linker chain length observed was **5b** > **5a** > **5c**. For example, due to the greatest linker chain length and thus enhanced flexibility, **5c** exhibited the lowest  $T_g$  value ( $T_g = 49^\circ\text{C}$ ). Similarly, **5a** exhibited a  $T_g$  value lower than **5b** ( $T_g$  **5a** =  $82^\circ\text{C}$  (Ouimet et al., *Biomacromolecules* **2013**, *14*, 854–61),  $T_g$  **5b** =  $108^\circ\text{C}$ ).

**Table 1.** Polymer characterization including drug loading percentage,  $M_w$ , PDI,  $T_g$ ,  $T_d$ , and contact angle measurements.

|                         | Drug loading (%) | $M_w$ (Da) | PDI | $T_g$ ( $^\circ\text{C}$ ) | $T_d$ ( $^\circ\text{C}$ ) | Contact angle (degrees) |
|-------------------------|------------------|------------|-----|----------------------------|----------------------------|-------------------------|
| <b>5a</b> <sup>10</sup> | 81               | 21,700     | 1.7 | 82                         | 332                        | 52                      |
| <b>5b</b>               | 79               | 18,300     | 1.3 | 108                        | 338                        | 34                      |
| <b>5c</b>               | 67               | 15,400     | 1.4 | 49                         | 251                        | 17                      |

**Relative Diacid (4) Hydrophobicity.** Measuring the diacid (**4**) water solubility proved difficult as diacid quickly degraded into ferulic acid. Therefore, a log P extrapolation method via HPLC was used. Capacity factor,  $k'$ , values were calculated by Equation 1 after the diacid retention times were obtained using HPLC (Table 2). Although not a direct correlation with solubility limits, the log P value indicates whether a compound is more or less soluble in water versus oil. With this, a lower log P value correlates to an increase in hydrophilicity. The calculated log P values in Table 2 demonstrate a trend where **4a** hydrophilicity < **4b** < **4c**.

**Table 2.** Calculated log P values for diacid molecules to elucidate their hydrophobicity

| Sample | Retention time (min) | Calculated log P values |
|--------|----------------------|-------------------------|
| 7.4a   | 19.19                | 2.2                     |
| 7.4b   | 15.35                | 2.0                     |
| 7.4c   | 12.92                | 1.8                     |

**Contact Angle Measurements.** To evaluate relative hydrophilicity, static contact angles were measured by dropping deionized water onto a pressed polymer disc surface as a factor that may influence ferulic acid release rates. The polymers were found to be relatively hydrophobic with contact angles ranging from 52 – 17 degrees (Table 1). As oxygen content increased, relative hydrophilicity increased as indicated by the decrease in contact angle, which is in accordance with other published glycol-containing polyanhydrides (Hou et al., *Macromol Biosci* **2007**, 7, 620-8). During measurements, the water droplet gradually expanded on the pressed polymer **5c** disc, whereas the water droplets for **5a** and **5b** remained stagnant, further indicating increased hydrophilicity as glycol functionality increased. Relative hydrophilicity may influence the degradation rate and subsequent bioactive release, as water penetration into the polymeric matrix is an important factor in degradation of polyanhydrides (Göpferich A, Tessmar J, *Adv Drug Deliv Rev* **2002**, 54, 911-31; Göpferich A, *Biomaterials* **1996**, 17, 103-14). Polymer **5a** exhibited the lowest contact angle value and also displayed the fastest release rates relative to polymers **5b** and **5c**.

**Polymer swelling measurements.** Polymer swelling was obtained by subtracting polymer wet weight from the dry weight and dividing by dry weight on a particular day. Differences in swelling values are due to increased hydrophilicity from the additional ethylene oxide groups. Extensive bulk erosion was presumably taking place as confirmed by the loss of structural integrity around day 6 for **5c**. Swelling acts as a mechanism by which polymer degradation within inner layers of polymer matrix is activated thus enabling both surface and bulk erosion.

**In Vitro Ferulic Acid Release.** Polymer degradation was measured by quantifying ferulic acid in degradation media measured by HPLC as its appearance is indicative of both anhydride and ester bond hydrolysis (*see*, Figure 5). Discs were used to enable uniform polymer degradation, without additional formulation steps, which may alter degradation and thus ferulic acid release. Relative hydrolysis rates of the hydrolytically labile bonds was not

apparent as diacid absorbance ( $R_t = 15.35$  and  $12.92$  min for **4b** and **4c**, respectively) was minimal at the observed wavelengths. Additionally, diacid solubility in PBS varied with glycol content. Detection of **1** ( $R_t = 2.98$  min) indicated complete ester and anhydride bond hydrolysis with no decomposition peaks observed.

The degradation media pH was monitored throughout the *in vitro* release tests. During polymer degradation, pH was always less than the initial pH = 7.4 (Figure 6). An initial state of swelling is observed for the FA (tetraglycolic) samples. Swelling is referred to as imbibing water by a polymer system, resulting in an increase in volume (Siegel RA, Rathbone MJ. Overview of Controlled Release Mechanisms. In: Siegel RA, Rathbone MJ, Siepmann J, editors. Fundamentals and Applications of Controlled Release Drug Delivery. New York: Springer; 2012. pp. 19-43). Water enters the polymer relatively rapidly due to ethylene oxide groups' ability to hydrogen bond and attracts water.

Initial slower ferulic acid release observed for polymer **5c** is presumably due to initial water uptake and subsequent polymer degradation resulting in decreased intra-polymer pH, causing a pH gradient between the discs' surface and interior. Such a gradient presumably caused swelling to continue until a critical osmotic pressure was attained within the disc, at which point the degradation products were released. Once the degradation products were released from the disc, a larger internal surface area was available for erosion to occur, thus leading to an increased release rate. Difference in release rates (measured by slope of line) was attributed to the increased hydrophilicity due to the addition of ethylene glycol derivatives into the polymer backbone; release rates increased with **5c** > **5b** > **5a** (8.02, 5.16, 0.29 for **5c**, **5b**, and **5a**, respectively).

*Antioxidant Assay.* A radical quenching assay was used to determine polymer degradation media antioxidant activity to ensure synthetic methods and release conditions did not influence ferulic acid activity (see, Figure 7). The DPPH reduction percentage was expected to increase with increasing antioxidant activity, which is directly correlated to antioxidant concentration.

## Conclusion


Compounds with antioxidant activity such as ferulic acid exhibit beneficial therapeutic properties to combat oxidative stress, but need better delivery. Such drug delivery systems are finding significant and diverse applications ranging from biomaterials to consumer products. Our approach is to incorporate glycol groups into the main chain of the polymer via chemical incorporation to tune the drug release rate and alter polymer properties was successful. Increasing the hydrophilicity enhances the ability to not only tune ferulic

acid release depending on intended application, but also alter physicochemical properties. These biodegradable polymers can be beneficial for short-term drug delivery systems with an emphasis on utilizing glycol functionality to tailor antioxidant-based polymer physicochemical properties and release profiles.

## EXAMPLE 2

### *Ferulic acid polymer microspheres.*

Oxidative stress causes DNA damage leading to many debilitating diseases. As described herein, a ferulic acid-based polymer that degrades within three weeks was designed and synthesized. As the polymer degrades in the presence of water, ferulic acid is released. Ferulic acid is a potent antioxidant with radical scavenging and photoprotective properties useful to combat oxidative stress and therefore used in cosmetics as a topical antioxidant in anti-aging remedies and sunscreens.



Several delivery systems employed in cosmetics and personal care that utilize entrapment or adsorption technologies include emulsions, vesicles such as liposomes and hollow microparticles (empty with no drug), and suspensions. One of the most common methods to topically deliver bioactives is through suspensions and emulsions. Micromulsions can be utilized to directly entrap actives, fragrances, or flavors as bulk emulsions have been primary formulations in the cosmetic industry. These microspheres are advantageous over using a disc in that the surface area is greatly increased, thus accelerating bioactive release. Furthermore, these microspheres can act as carriers to encapsulate other bioactive molecules for dual release and potential synergistic activity.

Accordingly, ferulic acid (FA)-containing polymers with a diglycolic linker were formulated into microspheres and subsequently characterized. Other polymers described herein (e.g., comprising a different bioactive or linker) may also be formulated into microspheres using similar methods as those described below.

## Materials and Methods

*Microsphere preparation.* Ferulic acid (FA)-containing polymer using a diglycolic linker was synthesized according to Example 1 and was formulated into microspheres using

an oil-in-water single emulsion solvent evaporation technique (Yeagy, *J Microencapsulation* 2006, 23, 643-53). In general, FA-containing polymer (0.50 g) was dissolved in dichloromethane (3 mL) and added drop-wise to 1% aqueous poly(vinyl alcohol) (PVA) solution (80 mL) at room temperature. The emulsion was homogenized for 2 min using an IKA Ultra-Turrax T8 homogenizer at approximately 10,000 rpm. The homogenized solution was left stirring for 2 h to allow microsphere formation by solvent evaporation. Microspheres were transferred to sterile 50 mL polypropylene conical tubes, washed with acidic water (pH 1) to remove residual PVA, centrifuged at 3,000 rpm for 10 min and supernatant decanted. This was repeated 5 times. Microspheres were frozen by placing the conical tubes in a dry ice/acetone bath and lyophilized for 24 h at -40 °C and 133x10<sup>-3</sup> mBar (LABCONO Freeze Dry System/Freezon 4.5).

*Size and morphology.* Size and morphology of the microspheres were determined using SEM. Images for each set of microspheres were obtained using an AMRAY-1830I microscope (AMRAY Inc.) after coating the samples with Au/Pd using a sputter coater (SCD 004, Blazers Union Limited). SEM images of each polymer microsphere sample were then analyzed using NIH ImageJ software. Distributions of particle diameter were obtained by evaluating > 50 particles per sample.

*Molecular weight.* Polymer precursors were analyzed via mass spectrometry to determine molecular weights. A Finnigan LCQ-DUO equipped with Xcalibur software and an adjustable atmospheric pressure ionization electrospray ion source (API-ESI Ion Source) was used with a pressure of  $0.8 \times 10^{-5}$  and 150 °C API temperature. Samples dissolved in methanol (< 10 µg/mL) were injected with a glass syringe. GPC was used to determine polymer weight-averaged molecular weight and polydispersity using a Perkin-Elmer liquid chromatography system consisting of a Series 200 refractive index detector, a Series 200 LC pump, and an ISS 200 autosampler. Automation of the samples and processing of the data was performed using a Dell OptiPlex GX110 computer running Perkin-Elmer TurboChrom 4 software with a Perkin-Elmer Nelson 900 Series Interface and 600 Series Link. Polymer samples were prepared for autoinjection by dissolving in dichloromethane (DCM, 10 mg/mL) and filtering through 0.45 µm poly(tetrafluoroethylene) syringe filters. Samples were resolved on a Jordi divinylbenzene mixed-bed GPC column (7.8 x 300 mm, Alltech Associates, Deerfield, IL) at 25 °C, with DCM as the mobile phase at a flow rate of 1.0 mL/min. Molecular weights were calibrated relative to broad polystyrene standards (Polymer Source Inc., Dorval, Canada).

*Thermal properties.* DSC measurements were carried out on TA Instrument Q200 to determine melting ( $T_m$ ) and glass transition ( $T_g$ ) temperatures. Measurements on samples (4-6 mg) heated under nitrogen atmosphere from  $-10\text{ }^{\circ}\text{C}$  to  $200\text{ }^{\circ}\text{C}$  at a heating rate of  $10\text{ }^{\circ}\text{C}/\text{min}$  and cooled to  $-10\text{ }^{\circ}\text{C}$  at a rate of  $10\text{ }^{\circ}\text{C}/\text{min}$  with a two-cycle minimum were performed. TA Instruments Universal Analysis 2000 software, version 4.5A was used to analyze the data. TGA was utilized for determining decomposition temperatures ( $T_d$ ) using a Perkin-Elmer Pyris 1 system with TAC 7/DX instrument controller and Perkin-Elmer Pyris software for data collection. Samples (5-10 mg) were heated under nitrogen atmosphere from  $25\text{ }^{\circ}\text{C}$  to  $400\text{ }^{\circ}\text{C}$  at a heating rate of  $10\text{ }^{\circ}\text{C}/\text{min}$ . Decomposition temperatures were measured at the onset of thermal decomposition.

*In vitro ferulic acid release.* FA release from polymer microspheres was studied at  $37\text{ }^{\circ}\text{C}$  in phosphate buffered saline (PBS) at pH 7.4 with agitation (60 rpm) to mimic physiological conditions. Triplicate samples of microspheres (20.0 mg) were suspended in 20 mL of PBS. After 12 hours, and every 24 hours after day 1, samples were centrifuged at 3,000 rpm for 5 minutes (Hettich Zentrifugen EBA12) to allow microspheres to settle to the bottom. Aliquots of the supernatant (15 mL) were collected and replaced with fresh PBS (15 mL). Spent media was analyzed via high-performance liquid chromatography (HPLC). The degradation products were analyzed and quantified via HPLC using an XTerra® RP18  $5\text{ }\mu\text{m}$   $4.6\times 150\text{ mm}$  column (Waters, Milford, MA) on a Waters 2695 Separations Module equipped with a Waters 2487 Dual  $\lambda$  Absorbance Detector. All samples were filtered using  $0.22\text{ }\mu\text{m}$  poly(vinylidene fluoride) syringe filters and subsequently injected ( $20\text{ }\mu\text{L}$ ) using an autosampler. The mobile phase was comprised of 50 mM  $\text{KH}_2\text{PO}_4$  with 1 % formic acid in DI water at pH 2.5 (65 %) and acetonitrile (35 %) run at  $1\text{ mL}/\text{min}$  flow rate at ambient temperature. Absorbance was monitored at  $\lambda = 320\text{ nm}$ . Amounts were calculated from known concentrations of standard FA solutions.

## Results and Discussion

The microsphere  $M_w$  and  $T_g$  were determined and compared to the values obtained for the unprocessed polymers (Table 3). A slight  $M_w$  decrease and increase in PDI compared to the unprocessed polymer was observed as expected due to the water exposure during formulation. The changes in  $T_g$  values decreased post formulation, but maintained above  $37\text{ }^{\circ}\text{C}$ , which ensure their shape will remain if used *in vivo*.

**Table 3.** Molecular weight, MW (polymer and microspheres), glass transition temperature, Tg (polymer and microspheres), and % yield (microspheres).

|         | <i>Mw (Da)</i><br><i>Polymer (PDI)</i> | <i>Mw (Da)</i><br><i>Microspheres</i> | <i>Tg (°C)</i><br><i>polymer</i> | <i>Tg (°C)</i><br><i>microspheres</i> | <i>% Yield</i><br><i>microspheres</i> |
|---------|----------------------------------------|---------------------------------------|----------------------------------|---------------------------------------|---------------------------------------|
| Polymer | 18,300 (1.3)                           | 15,500 (1.5)                          | 108                              | 80                                    | 83                                    |

Microspheres 2-27  $\mu\text{m}$  in diameter were obtained in 83 % yield without aggregation and are represented in Figure 8A. Smooth microsphere surfaces are important for uniform bioactive release. Additionally, size distribution, homogenization speed and polymer concentration may be varied.

The polymer microsphere's *in vitro* degradation was measured by the appearance of ferulic acid release in degradation media via HPLC. FA detection with a 3.71 minute retention time indicated complete of anhydride and ester bond hydrolysis. The polymer microspheres released 100 % ferulic acid over 10 days compared to polymer discs, which took 20 days for total release (*see*, Figure 8B).

The invention described herein also comprises compositions, devices, methods of use and methods of treatment which are disclosed herein, *e.g.*, in Example 1 and Example 2.

All publications cited herein are incorporated herein by reference. While in this application certain embodiments of invention have been described, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that certain of the details described herein may be varied without departing from the basic principles of the invention.



The use of the terms “a” and “an” and “the” and similar terms in the context of describing embodiments of invention are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (*i.e.*, meaning “including, but not limited to”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. In addition to the order detailed herein, the methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (*e.g.*, “such as”) provided herein, is intended merely to better illuminate embodiments of invention and

does not pose a limitation on the scope of the invention unless otherwise specifically recited in the claims. No language in the specification should be construed as indicating that any non-claimed element as essential to the practice of the invention.


## CLAIMS

What is claimed is:

1. A polymer selected from:



and






wherein  $R_1$  is  $OCH_3$  and  $R_2$  is H;  $R_1$  is  $OCH_3$  and  $R_2$  is  $OCH_3$ ; or  $R_1$  is H and  $R_2$  is H;  
 wherein  $y$  is 4 or more;  
 and wherein  $n$  is 2 or more.

2. The polymer of claim 1, wherein  $R_1$  is  $OCH_3$  and  $R_2$  is H.
3. The polymer of claim 1, wherein  $R_1$  is  $OCH_3$  and  $R_2$  is  $OCH_3$ .
4. The polymer of claim 1, wherein  $R_1$  is H and  $R_2$  is H.

5. A microsphere comprising a polymer as described in any one of claims 1-4.

6. A diacid selected from:



wherein  $R_1$  is  $OCH_3$  and  $R_2$  is H;  $R_1$  is  $OCH_3$  and  $R_2$  is  $OCH_3$ ; or  $R_1$  is H and  $R_2$  is H;  
and

wherein  $y$  is 4 or more.

7. The diacid of claim 6, wherein  $R_1$  is  $OCH_3$  and  $R_2$  is H.

8. The diacid of claim 6, wherein  $R_1$  is  $OCH_3$  and  $R_2$  is  $OCH_3$ .

9. The diacid of claim 6, wherein  $R_1$  is H and  $R_2$  is H.

10. A pharmaceutical composition comprising a diacid, polymer or microsphere as described in any one of claims 1-9 and a pharmaceutically acceptable carrier.

11. A cosmetic comprising a diacid, polymer or microsphere as described in any one of claims 1-9.
12. A sunscreen comprising a diacid, polymer or microsphere as described in any one of claims 1-9.
13. A method to reduce oxidative stress in a mammalian cell, comprising administering a diacid, polymer or microsphere as described in any one of claims 1-9 to the mammal.
14. A method to prevent photodamage to a mammal's skin, comprising administering a diacid, polymer or microsphere as described in any one of claims 1-9 to the mammal.
15. A method to treat a disorder associated with oxidative stress in a mammal, comprising administering a diacid, polymer or microsphere as described in any one of claims 1-9 to the mammal.
16. The method of any one of claims 13-15, wherein the diacid, polymer or microsphere is administered topically.
17. A diacid, polymer or microsphere as described by any one of claims 1-9 for use in medical treatment.
18. The use of a diacid, polymer or microsphere as described in any one of claims 1-9 to prepare a medicament useful for reducing oxidative stress in a mammalian cell.
19. The use of a diacid, polymer or microsphere as described in any one of claims 1-9 to prepare a medicament useful for preventing photodamage to a mammal's skin.
20. The use of a diacid, polymer or microsphere as described in any one of claims 1-9 to prepare a medicament useful for treating a disorder associated with oxidative stress in a mammal.
21. A diacid, polymer or microsphere according to any one of claims 1-9 for use in reducing oxidative stress.

22. A diacid, polymer or microsphere according to any one of claims 1-9 for use in preventing photodamage to a mammal's skin.
23. A diacid, polymer or microsphere according to any one of claims 1-9 for use in treating a disorder associated with oxidative stress in a mammal.
24. A hydrogel comprising (a) a polymer as described in any one of claims 1-4; and (b) a hydrophilic polymer that is blended with the polymer of part (a).
25. The hydrogel of claim 24, wherein the ratio of the polymer as described in any one of claims 1-4 and the hydrophilic polymer ranges between about 1:9 to about 1:1.
26. The hydrogel of claim 24 or 25, wherein the hydrophilic polymer comprises poly(N-vinyl-2-pyrrolidone), poly(vinyl alcohol) or poly(ethylene oxide).
27. The hydrogel of claim 26, wherein the hydrophilic polymer is poly(N-vinyl-2-pyrrolidone).
28. The hydrogel of any one of claims 24-27, wherein the polymer as described in any one of claims 1-4 is physically crosslinked with the hydrophilic polymer through hydrophobic interactions.
29. A method of making a hydrogel as described in any one of claims 24-28, comprising solvent casting (a) a polymer as described in any one of claims 1-4; and (b) a hydrophilic polymer; under conditions to provide a hydrogel.
30. The method of claim 29, further comprising cross-linking the polymer as described in any one of claims 1-4 with the hydrophilic polymer using ultraviolet radiation, gamma radiation or an external cross-linking agent.
31. A method for promoting wound healing in a mammal, comprising contacting a hydrogel as described in any one of claims 24-28 with a wound of the mammal.

32. A method of therapeutically treating the skin of a mammal, comprising contacting a hydrogel as described in any one of claims 24-28 with the skin of the mammal.
33. The use of a hydrogel as described in any one of claims 24-28 to prepare a medicament useful for promoting wound healing in a mammal.
34. The use of a hydrogel as described in any one of claims 24-28 to prepare a medicament useful for therapeutically treating the skin of a mammal.
35. A hydrogel according to any one of claims 24-28 for use in promoting wound healing in a mammal.
36. A hydrogel according to any one of claims 24-28 for use in therapeutically treating the skin of a mammal.
37. A hydrogel as described in any one of claims 24-28 for use in therapy.




FIG. 1

2/8




FIG. 2

Figure 3




Figure 4




Figure 5




Figure 6







Figure 7

Figure 8

A.



B.



## INTERNATIONAL SEARCH REPORT

1014/039970 16-10-2014

International application No.

PCT/US2014/039970

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C08G 63/06 (2014.01)

CPC - C08G 63/065 (2014.09)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - C08G 63/06, 63/664 (2014.01)

CPC - C08G 63/065, 63/605, 63/676 (2014.09)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
USPC - 528/209, 295.3, 301

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatBase, Orbit, STN, PubChem, Google Scholar

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                                                | Relevant to claim No. |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| A         | OUIMET et al. Biodegradable Ferulic Acid-containing Poly(anhydride-ester): Degradation Products with Controlled Release and Sustained Antioxidant Activity. Biomacromolecules, 14(3): 854-861, 11 March 2013. [Retrieved on 29 August 2014]. Retrieved from Internet. <URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595371>. entire document | 1-9, 24               |
| A         | US 2007/0213500 A1 (UHRICH) 13 September 2007 (13.09.2007) entire document                                                                                                                                                                                                                                                                        | 1-9, 24               |
| A         | US 2012/0058155 A1 (UHRICH et al) 08 March 2012 (08.03.2012) entire document                                                                                                                                                                                                                                                                      | 1-9, 24               |
| A         | WO 2012/139015 A1 (UHRICH et al) 11 October 2012 (11.10.2012) entire document                                                                                                                                                                                                                                                                     | 1-9, 24               |

☐ Further documents are listed in the continuation of Box C.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

29 August 2014

Date of mailing of the international search report

16 OCT 2014

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents  
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Blaine R. Copenheaver

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 10-23, 25-37  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.